Scarica l'app Stockscreener
3.98
2.69%
-0.11
Precedente Chiudi:
$4.09
Aprire:
$4.1
Volume 24 ore:
102.79K
Relative Volume:
1.43
Capitalizzazione di mercato:
$32.64M
Reddito:
$442.00K
Utile/perdita netta:
$-30.46M
Rapporto P/E:
-6.5246
EPS:
-0.61
Flusso di cassa netto:
$-27.47M
1 W Prestazione:
-15.14%
1M Prestazione:
-30.30%
6M Prestazione:
-46.22%
1 anno Prestazione:
-56.36%
Intervallo 1D:
$3.90
$4.18
Intervallo di 1 settimana:
$3.88
$4.80
Portata 52W:
$3.8181
$12.00
Clene Inc Stock (CLNN) Company Profile
Nome
Clene Inc
Settore
Industria
Telefono
801-676-9695
Indirizzo
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Confronta CLNN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| CLNN | 3.98 | 32.64M | 442.00K | -30.46M | -27.47M | -0.61 |
| KHC | 31.10 | 37.63B | 26.13B | 1.37B | 3.00B | 2.42 |
| GIS | 64.08 | 35.50B | 19.80B | 2.40B | 2.78B | 4.10 |
| K | 81.00 | 27.75B | 12.80B | 1.01B | 927.00M | 2.50 |
| MKC | 78.08 | 20.91B | 6.68B | 792.60M | 774.40M | 2.40 |
| HRL | 30.47 | 16.61B | 11.98B | 780.78M | 902.87M | 1.61 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-10-04 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-07-18 | Iniziato | H.C. Wainwright | Buy |
| 2022-05-02 | Iniziato | Canaccord Genuity | Buy |
| 2021-09-28 | Iniziato | Oppenheimer | Outperform |
Clene Inc Borsa (CLNN) Ultime notizie
Clene (NASDAQ:CLNN) Price Target Lowered to $83.00 at Canaccord Genuity Group - Defense World
AWM Investment Company, Inc. Expands Stake in Clene Inc - GuruFocus.com
Clene price target lowered to $83 from $86 at Canaccord - Yahoo Finance
ARMISTICE CAPITAL, LLC Acquires New Stake in Clene Inc - GuruFocus.com
Certain Warrants of Clene Inc. are subject to a Lock-Up Agreement Ending on 15-NOV-2024. - Marketscreener.com
Clene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Canaccord cuts Clene stock target, holds buy rating on FDA meeting - Investing.com UK
Clene Inc (CLNN) Q3 2024 Earnings: EPS of -$1.22 Beats Estimates, Revenue at $0.087 Million Misses Expectations - GuruFocus.com
Clene Inc. (CLNN) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Clene Announces Q3 2024 Results and ALS Drug Progress - TipRanks
Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights - The Manila Times
Clene Inc (CLNN-Q) QuotePress Release - The Globe and Mail
(CLNN) Technical Data - Stock Traders Daily
Clene to Meet with FDA Leadership to Discuss CNM-Au8 Biomarker for ALS Treatment - Vancity Buzz
IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership - Yahoo Finance
Clene Unveils Phase 3 Trial Design at NEALS - TipRanks
Clene Showcases Progress on CNM-Au8 for Neurodegenerative Diseases at Investor Conferences - Vancity Buzz
IBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor Conferences - Yahoo Finance
(CLNN) Trading Report - Stock Traders Daily
IBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private Placements - Yahoo Finance
Clene Secures $7.3M in Funding to Advance Neurodegenerative Disease Treatment - Vancity Buzz
Canaccord retains price target, buy rating on Clene shares post-webinar - Investing.com Canada
IBN Coverage: Clene (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences - Yahoo Finance
Clene Inc. to Present at Two Upcoming Investor Conferences in October - Vancity Buzz
Clene to Present at Upcoming October Conferences - The Manila Times
Clene (NASDAQ: CLNN) Announces Participation At Two Upcoming Investor Conferences - Barchart
Clene (NASDAQ:CLNN) Price Target Cut to $86.00 by Analysts at Canaccord Genuity Group - Defense World
Independent Chairman of the Board of Clene Picks Up 26% More Stock - Simply Wall St
Independent Chairman of the Board of Clene David Matlin Buys 26% More Shares - Yahoo Finance
Canaccord cuts Clene stock price target, maintains Buy rating By Investing.com - Investing.com South Africa
Canaccord cuts Clene stock price target, maintains Buy rating - Investing.com
Clene Secures $7.3 Million in Funding Through Direct Offering and Private Placements - Vancity Buzz
IBN Coverage: Clene (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M - Yahoo Finance
Clene Inc. director David Matlin buys $438k in company stock - Investing.com
Clene Inc. CEO purchases $47,500 in company stock - Investing.com India
Clene Inc. chief science officer purchases $97,432 in company stock By Investing.com - Investing.com Australia
Clene Inc. chief science officer purchases $97,432 in company stock - Investing.com India
IBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements - Yahoo Finance
Clene (CLNN) Gains Momentum In The Extended Session After Completing Investment Offering - Stocks Telegraph
Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility - The Manila Times
Clene Inc. CEO purchases $47,500 in company stock By Investing.com - Investing.com Australia
Insider Buying: Chief Science Officer Mark Mortenson Acquires Sh - GuruFocus.com
Clene Inc. Secures $7.3 Million in Funding Through Direct Offerings and Private Placements - Vancity Buzz
Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements - The Globe and Mail
Clene Inc. secures $7.3 million in stock and warrant sales By Investing.com - Investing.com Australia
Clene Inc. modifies loan terms and adjusts warrant exercise price - Investing.com India
Clene Inc Azioni (CLNN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Clene Inc Azioni (CLNN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mortenson Mark | Chief Science Officer |
Sep 30 '24 |
Buy |
4.75 |
20,512 |
97,432 |
28,949 |
| Etherington Robert Dee | Chief Executive Officer |
Sep 30 '24 |
Buy |
4.75 |
10,000 |
47,500 |
40,149 |
| Etherington Robert Dee | Chief Executive Officer |
Jul 29 '24 |
Option Exercise |
3.00 |
27,320 |
81,960 |
30,149 |
| General Resonance LLC | 10% Owner |
Apr 30 '24 |
Sale |
0.42 |
13,000 |
5,416 |
15,326,712 |
| General Resonance LLC | 10% Owner |
May 01 '24 |
Sale |
0.40 |
13,000 |
5,148 |
15,313,712 |
| General Resonance LLC | 10% Owner |
Apr 24 '24 |
Sale |
0.33 |
10,000 |
3,278 |
15,349,712 |
| General Resonance LLC | 10% Owner |
Apr 09 '24 |
Sale |
0.39 |
22,500 |
8,674 |
15,428,212 |
0.55%
0.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):